RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE, ALONE OR ASSOCIATED WITH HIGHDOSE CYTARABINE, FOLLOWED BY RESPONSE- AND AGE-TAILORED RADIOTHERAPY FOR IMMUNOCOMPETENT PATIENTS WITH NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
- Conditions
- primary chemotherapy of primary central nervous system lymphoma with high dose cytarabine plus methotrexateMedDRA version: 6.1Level: PTClassification code 10012818
- Registration Number
- EUCTR2005-001055-38-IT
- Lead Sponsor
- INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method